Close Menu

NEW YORK – Meridian Bioscience reported on Thursday that its fiscal fourth quarter revenues decreased 4 percent due to competitive pressures in the diagnostics market and pricing declines in its gastrointestinal products.

For the three months ended Sept. 30, the firm reported revenues of $50.8 million down from $53.1 million a year ago. It still beat the average consensus Wall Street estimate of $50.6 million.

Meridian reported Q4 diagnostics revenues of $33.4 million, down 9 percent year over year from $36.8 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.